Zevra Therapeutics, Inc., a rare disease therapeutics company, acquired Acer Therapeutics, Inc. in a transaction valued at approximately $76 million payable upon the achievement of certain regulatory and sales milestones.

The acquisition of Acer brings multiple rare disease assets and increases Zevra’s revenue potential with the addition of OLPRUVA, indicated for the treatment of certain urea cycle disorders (UCDs), and expands Zevra’s clinical portfolio with EDSIVO, currently in Phase 3 for vascular Ehlers-Danlos syndrome (vEDS).

“Today’s acquisition marks an exciting milestone for Zevra as we advance our mission to deliver therapies to the rare disease community,” said Neil McFarlane, President, and CEO of Zevra. “With our combined resources, expanded portfolio, and expert capabilities, we have the opportunity to make a tremendous impact on the lives of people with serious rare diseases. We are excited about the opportunities ahead for patients and remain focused on executing our strategic priorities to create long-term shareholder value.”

“The integration of Acer’s programs, capabilities and accomplished team complements and enhances Zevra’s portfolio, and advances our mission to bring life-changing therapies to patients with rare diseases,” said Joshua Schafer, chief commercial officer, and executive vice president of business development of Zevra. “Acer’s programs and capabilities are an excellent fit for Zevra, particularly OLPRUVA for UCDs, which is a serious rare genetic metabolic disorder. There is a high degree of overlap between the diagnosing physicians and Centers of Excellence where patients with UCDs and Niemann-Pick disease type C (NPC) are treated. We believe this overlap will allow us to realize synergies and scale to efficiently commercialize both programs.”